Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget Byrd, J. C., Smith, S., Wagner-Johnston, N., Sharman, J., Chen, A. I., Advani, R., Augustson, B., Marlton, P., Commerford, S. R., Okrah, K., Liu, L., Murray, E., Penuel, E., Ward, A. F., Flinn, I. W. 2019; 10 (38): 3827–30
[This corrects the article DOI: 10.18632/oncotarget.24310.].
View details for DOI 10.18632/oncotarget.27011
View details for PubMedID 31217910